A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma

• Published in: British journal of ophthalmology Vol. 93; no. 6; pp. 782 - 786
• Main Authors: How, A C S, Kumar, R S, Chen, Y-M, Su, D H, Gao, H, Oen, F T, Ho, C-L, Seah, S K, Aung, T
• Format: Journal Article
• Language: English
• Published: BMA House, Tavistock Square, London, WC1H 9JR BMJ Publishing Group Ltd 01.06.2009; BMJ Publishing Group; BMJ Publishing Group LTD
• Subjects: Aged; Aged, 80 and over; Amides - adverse effects; Amides - therapeutic use; Antihypertensive Agents - adverse effects; Antihypertensive Agents - therapeutic use; Bimatoprost; Biological and medical sciences; Cloprostenol - adverse effects; Cloprostenol - analogs & derivatives; Cloprostenol - therapeutic use; Cross-Over Studies; Female; Glaucoma; Glaucoma and intraocular pressure; Glaucoma, Angle-Closure - drug therapy; Glaucoma, Angle-Closure - physiopathology; Humans; Hypertension; Intraocular Pressure - drug effects; Male; Medical sciences; Metabolic disorders; Middle Aged; Miscellaneous; Ophthalmology; Prostaglandins F, Synthetic - adverse effects; Prostaglandins F, Synthetic - therapeutic use; Single-Blind Method; Treatment Outcome; Antiglaucomatous agent; Human; Eye disease; Primary; Ophthalmology; Comparative study; Angle closure glaucoma; Prostaglandin derivatives; Bimatoprost; Latanoprost
• ISSN: 0007-1161; 1468-2079
• DOI: 10.1136/bjo.2008.144535

Background/aims:To compare the intraocular pressure (IOP) lowering efficacy and side effects of latanoprost 0.005% and bimatoprost 0.03% in subjects with chronic primary angle closure glaucoma (PACG).Methods:This was an observer-masked randomised crossover study of 60 PACG subjects who received either latanoprost or bimatoprost for 6 weeks, after which they were crossed over to the other medication for another 6 weeks. The IOP-reducing effect of the medications was assessed by the reduction in IOP after 6 weeks of treatment compared with baseline.Results:Fifty-four subjects (80 eyes) completed the study. Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23). Adverse events were mild in both groups; however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01). Ocular irritation was the most frequently reported adverse event in both groups; 22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).Conclusions:Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG. Both drugs were well tolerated with mild ocular adverse events.